SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 19, 2012
INTERCEPT PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Registrant’s telephone number, including area code: (646) 747-1000
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Item 8.01 Other Events.
On December 19, 2012, Intercept Pharmaceuticals, Inc. issued a press release announcing that it has completed enrollment in POISE, its pivotal Phase 3 clinical trial of obeticholic acid (OCA) in primary biliary cirrhosis (PBC).
A copy of the press release is attached hereto as Exhibit 99.1
and is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.
(d) The following exhibit is filed with this report:
The press release contains hypertext links to information on our website and/or other websites. The information contained in or accessible from our website or any other website is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.